NASDAQ: CRDF
Cardiff Oncology Inc Stock Ownership - Who owns Cardiff Oncology?

Insider buying vs selling

Have Cardiff Oncology Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Gary W. PaceDirector2025-07-30275,000$2.45
$673.75kBuy
Gary W. PaceDirector2025-07-3015,000$2.45
$36.75kBuy

1 of 1

CRDF insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CRDF insiders and whales buy or sell their stock.

CRDF Shareholders

What type of owners hold Cardiff Oncology Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Robert Merrill Hunter7.52%5,065,004$14.23MInsider
Blackrock Inc5.92%3,985,536$11.20MInstitution
Vanguard Group Inc5.33%3,588,933$10.08MInstitution
Ra Capital Management LP4.88%3,290,000$9.24MInsider
Gary W. Pace4.64%3,124,113$8.78MInsider
Bridger Management LLC4.41%2,968,115$8.34MInsider
Laurion Capital Management LP3.66%2,465,872$6.93MInstitution
Pfizer Inc3.58%2,411,575$6.78MInstitution
Blair William Co3.29%2,213,606$6.22MInstitution
Acorn Capital Advisors LLC2.91%1,962,084$5.51MInstitution

1 of 3

CRDF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CRDF37.34%26.00%Net Buying
SABS35.08%64.92%Net Buying
TLSA3.61%0.00%
ARCT87.51%12.49%Net Buying
IMMX8.24%28.87%Net BuyingNet Buying

Cardiff Oncology Stock Ownership FAQ

Who owns Cardiff Oncology?

Cardiff Oncology (NASDAQ: CRDF) is owned by 37.34% institutional shareholders, 26.00% Cardiff Oncology insiders, and 36.66% retail investors. Robert Merrill Hunter is the largest individual Cardiff Oncology shareholder, owning 5.07M shares representing 7.52% of the company. Robert Merrill Hunter's Cardiff Oncology shares are currently valued at $13.47M.

If you're new to stock investing, here's how to buy Cardiff Oncology stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.